Alphatec bolstered its cash cushion during Q3, and hiked its full-year revenue forecast.
ATEC cratered hard after its latest earnings report, but insiders bought the dip. Here's a closer look.
Strong revenue growth and product innovations have Wall Street believing that this growth stock will rally 114% over the next 12 months.
This growth stock has tumbled in recent months, but analysts are forecasting more than 100% upside, based on Wall Street's mean price target.
Growth stocks such as Viking Therapeutics, Cresco Labs, and Alphatec Holdings continue to trade at a significant discount to analysts' consensus price target estimates.
Alphatec's revenue growth could lead to the company becoming profitable, causing the stock to rally. However, there are risks.